Originally published Jan. 10.

By Turna Ray

Takeda Pharmaceuticals is working with Zinfandel Pharmaceuticals to use a genetic test to determine which older people at high risk of getting Alzheimer's disease in the next five years should be enrolled in the development program for Actos as an Alzheimer's prevention drug.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.